Senior Director, Cardiometabolic Health Communications
Eli Lilly and Company
Summary
The Senior Director leads external communications for Lilly's on-market cardiometabolic medicines — currently Mounjaro (tirzepatide for type 2 diabetes), Zepbound (tirzepatide for obesity), and Foundayo (orforglipron for obesity) — as well as new indications and label expansions as they are approved. This role owns the consumer obesity communications strategy and leads global communications for all approved products, including coordination with international affiliates across 40+ markets.
Job description
Core Responsibilities
On-Market Brand Communications
- Own the external communications strategy for all approved CMH products, including earned media, thought leadership, advocacy partnerships, and consumer campaigns.
- Lead consumer obesity communications and develop innovative integrated campaigns that engage diverse audiences.
- Develop and maintain brand narratives for Mounjaro, Zepbound, and Foundayo, ensuring consistency across all channels and geographies.
- Support new indication launches and label expansions as they come through regulatory review, owning the communications strategy from pre-approval through post-launch.
Global Communications
- Lead the global communications strategy for approved products, ensuring consistent messaging and coordinated execution across international affiliates.
- Partner with affiliates to provide materials, messaging frameworks, and strategic guidance.
- Coordinate with the Scientific Innovation team to ensure smooth handoff of global communications as products move from regulatory approval into commercialization.
Medical Meeting Communications
- Lead communications strategy and execution for priority CMH medical meetings — including ADA, EASD, ACC, and AHA.
- Develop materials including press releases, media backgrounders, data summaries, and HCP-facing content timed to scientific presentations.
Issues Management & Media Relations
- Anticipate and lead communications challenges related to on-market products — including pricing and access, competitive dynamics, compounding, and safety.
- Partner with Issues and Crisis Communications Team and Enterprise Communications to maintain and develop relationships with A-list media; serve as spokesperson.
- Oversee on-market PR agency relationships, ensuring high-quality output and strategic alignment.
Team & Cross-Functional Collaboration
- Operate as an active and flexible member of the broader CMH Communications team and Global Corporate Communications team.
- Partner closely with marketing, medical affairs, regulatory, legal, and investor relations teams to align communications with business objectives.
Requirements
- Bachelor's degree in Communications, Public Relations, Journalism, or a related field
- 8+ years of communications experience with a strong background in consumer health, brand communications, and earned media
- Must be authorized to work in the United States on a full-time basis
- Demonstrated experience developing and implementing critical communications plans across traditional, digital, and social media
- Experience supporting a business unit and developing deep understanding of brand, medical, and commercial objectives
- Knowledge of diabetes, obesity, and related metabolic diseases is strongly preferred
- Experience in global communications and coordinating with international affiliates
- Strong issues management and crisis communications experience
- PR agency management experience
- Exceptional writing and storytelling skills
Benefits
- 401(k)
- Pension
- Vacation benefits
- Medical, Dental & Vision
- Prescription drug benefits
- Flexible spending accounts
- Life insurance
- Death benefits
- Employee assistance program
- Fitness benefits
- Employee clubs and activities
Company overview
Eli Lilly and Company, commonly known as Lilly, is a leading American multinational pharmaceutical corporation headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company has grown into one of the world's most valuable pharmaceutical enterprises, with operations in approximately 125 countries. Lilly specializes in developing and manufacturing innovative medicines across multiple therapeutic areas, including diabetes, oncology, neuroscience, immunology, and cardiometabolic diseases. The company is renowned for its groundbreaking work in insulin production, having been the first to mass-produce insulin and later developing the first commercially available insulin product in the U.S. Lilly's current portfolio includes blockbuster medications such as Mounjaro and Zepbound (tirzepatide) for diabetes and obesity, Trulicity (dulaglutide) for type 2 diabetes, Verzenio (abemaciclib) for breast cancer, and Taltz (ixekizumab) for autoimmune conditions. With approximately 47,000 employees worldwide, Lilly maintains a strong commitment to research and development, investing heavily in scientific innovation to address some of the world's most significant health challenges. The company operates with a mission to make life better for people around the world through the discovery and delivery of innovative medicines.